【摘要】：目的:本研究通過對不同劑量膽堿酯酶抑制劑多奈哌齊治療血管性癡呆的隨機對照試驗進行Meta分析,評價多奈哌齊治療血管性癡呆的有效性和安全性,為其臨床應用提供有效的循癥醫(yī)學證據(jù)。方法:計算機檢索中國學術期刊(CNKI)數(shù)據(jù)庫、維普中文數(shù)據(jù)庫、萬方數(shù)據(jù)庫、Pubmed、Cochrane Library、Embase等數(shù)據(jù)庫中有關多奈哌齊治療血管性癡呆的隨機對照試驗。依據(jù)納入排除標準收集文獻。對收集的669篇文章進行篩選,最終納入8篇符合條件的文獻,提取相關數(shù)據(jù),采用Revman5.3軟件進行統(tǒng)計分析,評價不同劑量多奈哌齊對血管性癡呆的療效及安全性。結果:多奈哌齊5mg/d組與多奈哌齊10mg/d組均較對照組治療血管性癡呆有明顯療效,可明顯提高簡易智力狀態(tài)檢查量表(MMSE)的分值,且無劑量相關性。統(tǒng)計學分析結果為多奈哌齊5mg/d組與對照組:I2=21%,WMD=0.74,95%CI(0.44,1.05);多奈哌齊10mg/d與對照組:I2=0%,WMD=1.10,95%CI(0.58,1.62);多奈哌齊10mg/d組與多奈哌齊5mg/d組:I2=0%,WMD=0.29,95%CI(-0.05,0.64)。結論:根據(jù)此系統(tǒng)評價結果,5mg、10mg多奈哌齊對血管性癡呆患者認知功能均有顯著改善作用,療效無明顯劑量相關性。
[Abstract]:Objective: to evaluate the efficacy and safety of Donepezil in the treatment of vascular dementia by Meta analysis in a randomized controlled trial of different doses of Donepezil, a cholinesterase inhibitor, in the treatment of vascular dementia. To provide effective medical evidence for its clinical application. Methods: the randomized controlled trials of Donepezil in the treatment of vascular dementia were searched by computer in the databases of Chinese academic journal (CNKI), Wip Chinese database, Wanfang database, Pubmed,Cochrane Library,Embase and so on. Collect documents according to the exclusion criteria. Six hundred and sixty-nine articles were selected and 8 articles were selected. The data were extracted and analyzed statistically with Revman5.3 software to evaluate the efficacy and safety of different doses of Donepezil in the treatment of vascular dementia. Results: Donepezil 5mg/d group and Donipezil 10mg/d group were more effective in treating vascular dementia than those in control group. The scores of (MMSE) in mini mental state examination scale were significantly increased, and there was no dose correlation between the two groups. The results of statistical analysis showed that the 5mg/d group and the control group were I2, WMD, 0.74, 95% CI (0.44, 1.05), and the 10mg/d and the control group were I 2? 0%, WMD? 1.10, 95% CI (0.58, 1.62). 10mg/d group and 5mg/d group: I2%, WMD 0.29,95% CI (- 0.05,0.64). Conclusion: according to the results of this systematic evaluation, 5mg and 10mg Donepezil could significantly improve cognitive function in patients with vascular dementia, and there was no significant dose correlation between the therapeutic effect and the cognitive function of the patients with vascular dementia.
【學位授予單位】：吉林大學
【學位級別】：碩士
【學位授予年份】：2017
【分類號】：R749.13

【參考文獻】

相關期刊論文 前10條

1 劉淑玲;施月仙;婁青;紀勇;;不同劑量多奈哌齊治療血管性認知障礙的Meta分析[J];山東醫(yī)藥;2013年42期

2 王愛華;;高壓氧治療血管性癡呆癥的療效觀察[J];中國實用醫(yī)藥;2013年20期

3 孫賢楨;郭志男;;血管性癡呆的診斷及治療進展[J];中國當代醫(yī)藥;2012年31期

4 郝文莉;;鹽酸多奈哌齊治療血管性癡呆33例臨床療效觀察[J];中國現(xiàn)代藥物應用;2010年08期

5 何小花;王雪峰;曾學清;王瑛;呂紅梅;;綜合康復治療血管性癡呆的臨床觀察[J];齊齊哈爾醫(yī)學院學報;2009年20期

6 李中明;徐沙麗;李哈妮;;鹽酸多奈哌齊治療血管性癡呆33例[J];醫(yī)藥導報;2008年10期

7 王彥;石文健;郝立科;紀茹英;;鹽酸多奈哌齊治療血管性癡呆臨床觀察[J];中國藥房;2006年18期

8 黎紅;何明大;黃旖旎;;腦心通膠囊對血管性癡呆模型大鼠海馬神經細胞靜息態(tài)[Ca~(2+)]i的影響[J];中藥藥理與臨床;2006年Z1期

9 張秀清,顧愛霞,朱日華;血管性癡呆的危險因素及防治進展[J];現(xiàn)代康復;2001年09期

10 賈建平;血管性癡呆的診斷和治療新進展[J];引進國外醫(yī)藥技術與設備;1999年12期

，

本文編號：2469972